Cargando…
Mechanism of inhibition of tumour growth by aspirin and indomethacin.
The growth of a 3-methylcholanthrene-induced fibrosarcoma of C3H mice was inhibited by aspirin and indomethacin. While the tumour contained relatively high concentrations of PGE2-like material, that were markedly diminished by indomethacin treatment, our results did not confirm the recently proposed...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1978
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009769/ https://www.ncbi.nlm.nih.gov/pubmed/365211 |
_version_ | 1782136183102373888 |
---|---|
author | Lynch, N. R. Castes, M. Astoin, M. Salomon, J. C. |
author_facet | Lynch, N. R. Castes, M. Astoin, M. Salomon, J. C. |
author_sort | Lynch, N. R. |
collection | PubMed |
description | The growth of a 3-methylcholanthrene-induced fibrosarcoma of C3H mice was inhibited by aspirin and indomethacin. While the tumour contained relatively high concentrations of PGE2-like material, that were markedly diminished by indomethacin treatment, our results did not confirm the recently proposed hypothesis that the anti-tumour effect arises from a restoration of depressed immune function. For example, mice that had completely eliminated their tumours under indomethacin administration were not immune to rechallenge. The tumour-bearing animals were not non-specifically immunodepressed, as their splenic PFC responses against SRBC were enhanced. However, while indomethacin augmented the PFC response in normal mice, this adjuvant effect was depressed in tumour-bearing animals. The spleen-cell PHA responses of tumour bearers were severely depressed, and such cells suppressed the PHA response of normal cells. Only after prolonged indomethacin treatment did animals (with comparable tumour burdens) show weak PHA responses and somewhat diminished suppressive activity. Possible alternative mechanisms, such as direct cytotoxicity, or inhibition of inflammation, phosphodiesterase activity, blood coagulation or calcium availability were not implicated (nor definitively excluded) in the anti-tumour effect. IMAGES: |
format | Text |
id | pubmed-2009769 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1978 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-20097692009-09-10 Mechanism of inhibition of tumour growth by aspirin and indomethacin. Lynch, N. R. Castes, M. Astoin, M. Salomon, J. C. Br J Cancer Research Article The growth of a 3-methylcholanthrene-induced fibrosarcoma of C3H mice was inhibited by aspirin and indomethacin. While the tumour contained relatively high concentrations of PGE2-like material, that were markedly diminished by indomethacin treatment, our results did not confirm the recently proposed hypothesis that the anti-tumour effect arises from a restoration of depressed immune function. For example, mice that had completely eliminated their tumours under indomethacin administration were not immune to rechallenge. The tumour-bearing animals were not non-specifically immunodepressed, as their splenic PFC responses against SRBC were enhanced. However, while indomethacin augmented the PFC response in normal mice, this adjuvant effect was depressed in tumour-bearing animals. The spleen-cell PHA responses of tumour bearers were severely depressed, and such cells suppressed the PHA response of normal cells. Only after prolonged indomethacin treatment did animals (with comparable tumour burdens) show weak PHA responses and somewhat diminished suppressive activity. Possible alternative mechanisms, such as direct cytotoxicity, or inhibition of inflammation, phosphodiesterase activity, blood coagulation or calcium availability were not implicated (nor definitively excluded) in the anti-tumour effect. IMAGES: Nature Publishing Group 1978-10 /pmc/articles/PMC2009769/ /pubmed/365211 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Lynch, N. R. Castes, M. Astoin, M. Salomon, J. C. Mechanism of inhibition of tumour growth by aspirin and indomethacin. |
title | Mechanism of inhibition of tumour growth by aspirin and indomethacin. |
title_full | Mechanism of inhibition of tumour growth by aspirin and indomethacin. |
title_fullStr | Mechanism of inhibition of tumour growth by aspirin and indomethacin. |
title_full_unstemmed | Mechanism of inhibition of tumour growth by aspirin and indomethacin. |
title_short | Mechanism of inhibition of tumour growth by aspirin and indomethacin. |
title_sort | mechanism of inhibition of tumour growth by aspirin and indomethacin. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009769/ https://www.ncbi.nlm.nih.gov/pubmed/365211 |
work_keys_str_mv | AT lynchnr mechanismofinhibitionoftumourgrowthbyaspirinandindomethacin AT castesm mechanismofinhibitionoftumourgrowthbyaspirinandindomethacin AT astoinm mechanismofinhibitionoftumourgrowthbyaspirinandindomethacin AT salomonjc mechanismofinhibitionoftumourgrowthbyaspirinandindomethacin |